Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - BioSpace

Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection  BioSpace

Japanese pharma firm Daiichi Sankyo sets up new research sites in US, Germany - BSA bureau

Japanese pharma firm Daiichi Sankyo sets up new research sites in US, Germany  BSA bureau

Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site - BioSpace

Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site  BioSpace

In Daiichi case, court upholds jury's $177.8M infringement ruling against Novartis - FiercePharma

In Daiichi case, court upholds jury's $177.8M infringement ruling against Novartis  FiercePharma

AstraZeneca, Daiichi hit first goal in pivotal breast cancer ADC trial, teeing up filings to chal...

AstraZeneca, Daiichi hit first goal in pivotal breast cancer ADC trial, teeing up filings to challenge Gilead  Fierce Biotech

USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo - BioSpace

USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo  BioSpace

Paving the way for Merck's buyout, Seagen loses arbitration dispute with Daiichi Sankyo over ADC ...

Paving the way for Merck's buyout, Seagen loses arbitration dispute with Daiichi Sankyo over ADC tech  Endpoints News

Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia - FiercePh...

Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia  FiercePharma

Daiichi Sankyo’s FLT3 Inhibitor Gets FDA Nod as First-Line AML Treatment - BioSpace

Daiichi Sankyo’s FLT3 Inhibitor Gets FDA Nod as First-Line AML Treatment  BioSpace